Chitosan as a novel nasal delivery system for vaccines

• Published in: Advanced drug delivery reviews 2001-09, Vol.51 (1), p.81-96
• Main Authors: Illum, L, Jabbal-Gill, I, Hinchcliffe, M, Fisher, A.N, Davis, S.S
• Format: Article
• Language: English
• Subjects: Administration, Intranasal; Animals; Chitin - administration & dosage; Chitin - analogs & derivatives; Chitosan; Diphtheria; Diphtheria Toxoid - administration & dosage; DNA delivery; Drug Delivery Systems; Humans; Influenza; Influenza Vaccines - administration & dosage; Nasal vaccines; Pertussis; Pertussis Vaccine - administration & dosage; Phase I clinical study; Vaccines - administration & dosage; Vaccines, DNA - administration & dosage
• ISSN: 0169-409X; 1872-8294
• DOI: 10.1016/S0169-409X(01)00171-5

A variety of different types of nasal vaccine systems has been described to include cholera toxin, microspheres, nanoparticles, liposomes, attenuated virus and cells and outer membrane proteins (proteosomes). The present review describes our work on the use of the cationic polysaccharide, chitosan as a delivery system for nasally administered vaccines. Several animal studies have been carried out on influenza, pertussis and diphtheria vaccines with good results. After nasal administration of the chitosan-antigen nasal vaccines it was generally found that the nasal formulation induced significant serum IgG responses similar to and secretory IgA levels superior to what was induced by a parenteral administration of the vaccine. Animals vaccinated via the nasal route with the various chitosan-antigen vaccines were also found to be protected against the appropriate challenge. So far the nasal chitosan vaccine delivery system has been tested for vaccination against influenza in human subjects. The results of the study showed that the nasal chitosan influenza vaccine was both effective and protective according to the CPMP requirements. The mechanism of action of the chitosan nasal vaccine delivery system is also discussed.